PBAC's latest decision on Brexpiprazole: Recommended (2025). Considered for Treatment of schizophrenia in adults. The submission requests listing of a new 0.5 mg tablet strength to facilitate dose titration in patients who require doses less than 1 mg.
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
2
first 2017
Submissions
2
2017 → 2025
Eligible population
Adults with schizophrenia requiring dose titration or doses less than 1 mg.
Therapy area
Mental health
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
currently listed strengths of brexpiprazole tablet (1 mg, 2 mg, 3 mg, 4 mg)
Economic model
Cost-minimisation
Budget impact
$2M
ICER note
Cost-minimisation analysis; no ICER calculated as the 0.5 mg strength is not expected to provide substantial or clinically relevant improvement in efficacy or reduction of toxicity over existing strengths.
Submission history
Mar 2017: Recommended with restriction · Authority Required